Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See
full details
.
I Agree
×
Join today and have your say! It’s FREE!
Join Now
Sign In
Become a member today, It's free!
We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.
Join Today
or
Sign in with existing account
Privacy Policy
|
Disclaimer
Sign In
Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Remember me
Forgot Password?
Sign In
or
Sign Up
Privacy Policy
|
Disclaimer
Please Try Again
{{ error }}
Send my password
Submit
Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.
Become a member today, It's free!
We will not release or resell your information to third parties without your permission.
Linking with Facebook:
Stockhouse membership requires an email address which must be shared by Facebook.
By default, joining or signing in using your Facebook account will work and the email address will be shared by Facebook automatically.
If you change your Facebook permissions to restrict Stockhouse from receiving your email while joining or signing in to Stockhouse then it will fail.
Please do not modify the permission settings during sign-in.
Sign in with Facebook
Return to Signup Options
Home
Community
Bullboards
Blogs
Groups
Messages
Markets
Stocks
TSX
TSXV
CSE
NASDAQ
NYSE
NYSE American
Cryptocurrency
Currencies
Market Movers
Bonds
News
Featured News
Trending News
Canadian Press Releases
US Press Releases
Video
Editorial
Thematic Insights
Independent Reports
Interviews
Buzz on the Bullboards
Portfolio
Watchlist
Portfolio
Showcase Companies
DealRoom
Quote
|
Bullboard
|
News
|
Opinion
|
Profile
|
Peers
|
Filings
|
Financials
|
Options
|
Price History
|
Ratios
|
Ownership
|
Insiders
|
Valuation
Bullboard - Stock Discussion Forum
Oncolytics Biotech Inc
ONCY
Primary Symbol:
T.ONC
Healthcare
Biotechnology
Oncolytics Biotech Inc. is a biotechnology company. The Company is focused on developing pelareorep, an intravenously delivered immunotherapeutic agent that activates the innate and adaptive immune systems and weakens tumor defense mechanisms. This compound induces anti-cancer immune responses and promotes an inflamed tumor phenotype turning cold tumors hot through innate and adaptive immune...
responses to treat a variety of cancers. This improves the ability of the immune system to fight cancer, making tumors more susceptible to a broad range of oncology treatments. The Company’s primary focus is to advance its programs in hormone receptor-positive / human epidermal growth factor 2- negative (HR+/HER2-) metastatic breast cancer and advanced/metastatic pancreatic ductal adenocarcinoma to phase 3 licensure-enabling studies. In addition, it is exploring opportunities for registrational programs in other gastrointestinal cancers through its GOBLET platform study.
see more
Join the community and start posting on the bullboards today. It's free.
You are already a member! Please enter your password to sign in.
Remember me
Forgot password?
Back
Submit
By providing my email, I consent to receiving messages from Stockhouse.
Create a portfolio watchlist today. It's free.
You are already a member! Please enter your password to sign in.
Remember me
Forgot password?
Back
Submit
By providing my email, I consent to receiving messages from Stockhouse.
Add To Watchlist
Bullboard (TSX:ONC)
New Post
View:
Posts & Comments
Threaded Posts
Prev
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
...
Next
(196)
•••
Buckhenry
X
View Profile
View Bullboard History
Comment by
Buckhenry
on May 26, 2024 3:09pm
RE:RE:RE:ONCY presents 2 posters at ASCO 2024
I feel soooo much better hearing for the 100th time that his stock is about to explode very very very very very soon. Got my finger on the buy button fir my new yacht.... cuddos to
...more
(70)
•••
laroplex
X
View Profile
View Bullboard History
Comment by
laroplex
on May 26, 2024 10:38am
RE:RE:ONCY presents 2 posters at ASCO 2024
These 2 posters ONCY is presenting on Saturday should be key to attracting that big Pharma partner we have all been waiting for(buy-out or partnership).....I got a gut feeling our s/p willl start to
...more
Strong Q1 and Muscular Q2 Outlook for Cannabis Edibles Leader
posted May 26, 2024 9:00am by
Indiva Ltd
-
|
Gross revenue Q1 was $10.6 million, a 2.6% increase YOY as the company replaced over 50% of its net revenue from Wana’s shift to contract manufacturing and a regulatory change with its own core brands, namely Pearls gummies. Post Q1, April 2024 was a record month for net revenue, with growth driven by continued strength in Pearls, revenue from No Future gummies and Indiva Blips ...read more
(5836)
•••
Noteable
X
View Profile
View Bullboard History
Comment by
Noteable
on May 26, 2024 9:40am
RE:ONCY presents 2 posters at ASCO 2024
“The two abstracts that we are sharing at ASCO this year are in synch with our mission of advancing pelareorep towards registrational trials" https://www.financialnewsmedia.com/news-oncy/
...more
(5836)
•••
Noteable
X
View Profile
View Bullboard History
Comment by
Noteable
on May 26, 2024 9:08am
RE:RE:RE:RE:ONCY presents 2 posters at ASCO 2024
May 24, 2024 - Regeneron Pharmaceuticals released underwhelming bispecific Phase I/II data on its ongoing bispecific antibody study in patients with advanced solid tumors. REGN7075 is a
...more
(5836)
•••
Noteable
X
View Profile
View Bullboard History
Post by
Noteable
on May 26, 2024 8:49am
OT:Cancer Radiopharmaceutical Therapy reports Adverse Events
May 24, 1014 - J&J reports 4 patient deaths in early stage prostate cancer. Four patients died in Johnson & Johnson's Phase I study for its investigational targeted
...more
(5836)
•••
Noteable
X
View Profile
View Bullboard History
Comment by
Noteable
on May 25, 2024 10:08pm
RE:RE:RE:RE:RE:RE:RE:RE:RE:CD8+ TiLs and T-cell exhaustion
Bracelet-1 demonstrated that pelareorep is an effective immunotherapy agent without an immune checkpoint inhibitor AND that pelareorep is more effective than chemotherapy (I.e. paclitaxel).
...more
(5836)
•••
Noteable
X
View Profile
View Bullboard History
Comment by
Noteable
on May 25, 2024 9:37pm
RE:RE:RE:RE:RE:RE:RE:RE:CD8+ TiLs and T-cell exhaustion
Results from ONCY's AWARE-1 study showed that pelareorep treatment upregulated tumor PD-L1 expression, induced the generation and expansion of T cell clones, promoted tumor infiltration of CD8
...more
(5836)
•••
Noteable
X
View Profile
View Bullboard History
Comment by
Noteable
on May 25, 2024 9:27pm
RE:RE:RE:RE:RE:RE:RE:CD8+ TiLs and T-cell exhaustion
" Unlike other approved anti-PD-L1 antibodies, avelumab has a native Fc region that retains FcγR binding capability." Avelumab is cleared faster and has a shorter half-life than other anti
...more
(5836)
•••
Noteable
X
View Profile
View Bullboard History
Comment by
Noteable
on May 25, 2024 8:51pm
RE:RE:RE:RE:RE:RE:CD8+ TiLs and T-cell exhaustion
For tthose traders who are trying to exploit the BRACELET-1 cohort 3 results by implying something that is not .. cohort 3 involved the immune checkpoint inhibitor avelumab which is the only PD-(L)1
...more
(957)
•••
canadafan
X
View Profile
View Bullboard History
Comment by
canadafan
on May 25, 2024 2:59pm
RE:RE:RE:RE:ONCY presents 2 posters at ASCO 2024
Notice the professional Baskers, go away on the weekend. They work extra hard all week, to discredit any good news. The two recent abstracts, actually complicated in their own right
...more
(5836)
•••
Noteable
X
View Profile
View Bullboard History
Comment by
Noteable
on May 25, 2024 1:07pm
RE:RE:RE:ONCY presents 2 posters at ASCO 2024
February 2024 - The Lancet - Treatment of Metastatic Pancreatic Cancer: 25 years of innovation with little progress for patients " Despite an explosion of clinical trials and
...more
(5836)
•••
Noteable
X
View Profile
View Bullboard History
Comment by
Noteable
on May 25, 2024 12:40pm
RE:RE:ONCY presents 2 posters at ASCO 2024
As there had been no first line treatment for mPDAC, in February 2024 the FDA resorted to approving an already established chemotherapy combination treatment for this rare disease condition
...more
(5836)
•••
Noteable
X
View Profile
View Bullboard History
Comment by
Noteable
on May 25, 2024 11:58am
RE:ONCY presents 2 posters at ASCO 2024
A primer on pancreatic cancer .... and current treatment options. https://www.cancer.gov/types/pancreatic/patient/pancreatic-treatment-pdq Stage IV (metastatic) pancreatic cancer has a five-year
...more
(5836)
•••
Noteable
X
View Profile
View Bullboard History
Post by
Noteable
on May 25, 2024 9:33am
ONCY presents 2 posters at ASCO 2024
Oncolytics Biotech ® Inc., ($ONCY $ONC) a leading clinical-stage company specializing in immunotherapy for oncology, presented two abstracts at the 2024 American Society of Clinical
...more
(5836)
•••
Noteable
X
View Profile
View Bullboard History
Comment by
Noteable
on May 25, 2024 8:43am
RE:RE:RE:RE:RE: Pelareorep + Paclitaxel = ADC/HER2 failed breast cancer
Key one (1) year biomarker and safety findings of ONCY's Phase 2 Bracelet-1 breast cancer study: Association between T cell expansion and efficacy measures: A statistically
...more
Prev
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
...
Next
Thank You
Your Report has been submitted.
Report Abusive Content
×
Close
Sign up to get access
You are already a member! Please enter your password to sign in.
Remember me
Forgot password?
Back
Submit
By providing my email, I consent to receiving messages from Stockhouse.
The Market Update
{{currentVideo.title}}
{{currentVideo.relativeTime}}
< Previous bulletin
Next bulletin >
A daily snapshot of everything
from market open to close.
{{currentVideo.companyName}}
{{currentVideo.intervieweeName}}
{{currentVideo.intervieweeTitle}}
{{currentVideo.headline}}
{{currentVideo.link1Text}}
{{currentVideo.link2Text}}
< Previous
{{moreVideoText}}
Next >